| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
* Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Medical School, Houston, TX 77030;
Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104; and
Graduate School of Biomedical Sciences, Houston, TX 77030
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Elevations in extracellular adenosine can result from either an increase in intracellular adenosine followed by release into the extracellular space, or by the release of adenine nucleotides followed by their extracellular catabolism into adenosine (13). Intracellularly, adenosine can be generated from the hydrolysis of S-adenosylhomocysteine (14), or by the dephosphorylation of AMP by cytosolic nucleotidases (15). Extracellularly, adenosine can be generated following the release and dephosphorylation of adenine nucleotides (13). ATP and AMP are released from activated granulocytes (16, 17), and ADP is released from platelets upon degranulation (18). Bronchial epithelium can release ATP under basal conditions (19) and upon perturbation of the plasma membrane (20, 21, 22). Extracellular ATP and ADP can be converted into AMP by extracellular apyrases such as CD39 and alkaline phosphatase (23, 24, 25), and AMP can then be converted into adenosine by ecto-5'-nucleotidase (CD73) or alkaline phosphatase (24, 25). Examining the contribution of these various pathways to the generation of extracellular adenosine following injury could provide insight into novel approaches to control the production of this potent regulator of inflammation and tissue damage.
Emerging evidence suggests that concerted mechanisms likely exist for increased extracellular adenosine formation. CD73 forms adenosine from the dephosphorylation of extracellular AMP (26). CD73 is up-regulated following hypoxia as part of a response to increase local extracellular adenosine levels (27, 28, 29). This mechanism has been validated by subjecting CD73-deficient mice to hypoxic conditions and demonstrating that endothelial barrier function is compromised (30). Other studies have shown that CD73 contributes to adenosine-mediated effects on coronary blood vessels (31) and in the kidney (32). Thus, the dephosphorylation of extracellular AMP by CD73 may represent a major route of adenosine formation in tissue injury.
Adenosine levels are elevated in the lungs of asthmatics (33, 34), and in various animal models of chronic lung disease (35, 36, 37). However, the mechanisms governing adenosine formation in the injured lung are not known. The major focus of this study was to examine the contribution of CD73 to adenosine formation following injury in the lung. This was accomplished by subjecting CD73-deficient mice to bleomycin-induced lung injury. Results demonstrated that exposure of mice to bleomycin results in elevated adenosine levels in conjunction with elevations in CD73 enzymatic activity. Exposure of CD73-deficient mice to bleomycin demonstrated that this enzyme is responsible for nearly all the adenosine formed in response to bleomycin-induced lung injury. Moreover, the lack of adenosine formation in bleomycin-treated CD73-deficient mice was associated with enhanced inflammation and fibrosis, suggesting that adenosine is protective in this model.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Genotypes of CD73 mice (30) backcrossed onto C57BL/6J to the fifth generation were tracked with the following primers: wild-type allele, sense primer 5'-CTCTGCATTGCAGCCTGAAG-3' and antisense primer 5'-CGATGTCCACACCTCGAACT-3'; knockout allele, sense 5'-CCAGCTCATTCCTCCCACTCATG-3' and antisense 5'-CCATTTGAATACTAGCTTCCAGG-3'. Six to 8-wk-old female C57/BL6J mice were purchased from Harlan. All mice were maintained and housed in accordance with the Animal Care Committee at the University of Texas Health Science Center at Houston and National Institutes of Health guidelines. Mice were housed in ventilated cages equipped with microisolator lids and maintained under strict containment protocols. No evidence of bacterial, parasitic, or fungal infection was found, and serologies on cage littermates were negative for 12 of the most common murine viruses.
Bleomycin exposures
Animals homozygous for the CD73 null allele were designated CD73–/–. Animals homozygous for the CD73 wild-type allele were designated CD73+/+. Six to 8-wk-old male and female littermate CD73+/+ and CD73–/– mice from heterozygous mating pairs were used. Mice anesthetized with avertin were tracheostomized, and 3.5 U/kg bleomycin (Blenoxane; Bristol-Myers Squibb) diluted in 60 µl of normal saline or 60 µl of normal saline alone was instilled intratracheally. Endpoints were measured 14 days postchallenge.
Quantification of lung adenosine levels
Mice were anesthetized, and the lungs were rapidly removed and frozen in liquid nitrogen. Adenine nucleosides were extracted from frozen lungs using 0.4 N perchloric acid as described previously (38), and adenosine was separated and quantified using reversed phase HPLC.
Measurement of CD73 enzyme activity and Western blotting
Mice were anesthetized, and lungs were removed and frozen in liquid nitrogen. Membrane fraction proteins were extracted and used to assay CD73 protein levels by Western blot. CD73-specific activity was also measured in membrane fractions using the following procedure: 1 µg of total protein was preincubated at room temperature with 200 nM deoxycoformycin in 0.1 M HEPES (pH 7.4), with 50 µM MgCl, with or without 
-methylene ADP (APCP; Sigma-Aldrich). Next, samples were incubated at 37°C for 30 min in the presence of 100 µM AMP. AMP hydrolytic activity (AMPase) was measured by determining adenosine concentrations with reversed phase HPLC (38). Western analysis was conducted using Ab generated against the peptide sequence NDVHSRLEQTSDDSTK, near the N terminus (Bethyl Laboratories). One hundred micrograms of membrane fraction protein per lane were run on a 7.5% polyacrylamide gel and transferred to a PVDF membrane for analysis via chemiluminescence.
RNA Extraction
Mice were anesthetized, and the lungs were rapidly removed and frozen in liquid nitrogen. RNA was isolated from frozen lung tissue using TRIzol reagent (Invitrogen Life Technologies). RNA samples were then DNase treated and subjected to quantitative real-time RT-PCR. Analysis of 1-procollagen, osteopontin (OPN), IL-1, TGF-1, TNF-, plasminogen activator inhibitor-1 (PAI-1), and tissue inhibitor of metalloproteinase-1 (TIMP-1) was performed using quantitative RT-PCR as described previously (37, 39). CD73 transcript was measured by quantitative RT-PCR using primers specific for the CD73 mRNA (sense, 5'- TTGGCAAATACCTGGGCTAC-3'; antisense 5'- AGGTTTCCCATGTTGCATTC-3').
Histological analysis
Mice were anesthetized, and the lungs were perfused with 5–10 ml of PBS and then pressure infused with 4% paraformaldehyde in PBS and fixed overnight at 4°C. Fixed lungs were rinsed in PBS, dehydrated through graded ethanol washes, and embedded in paraffin. Sections (5 µm) were collected on slides and stained with H&E or Masson’s Trichrome according to the manufacturer’s instructions.
Bronchial alveolar lavage (BAL) and cellular differentials
Mice were anesthetized and tracheally intubated with a blunted 21-gauge needle. Lungs were lavaged with 1–2 ml of PBS, and the recovered BAL fluid was processed for the determination of cellular differentials. Briefly, total cell counts were performed on initial lavaged aliquots, and cellular differentials (300 cells/sample) were conducted on cells cytospun onto slides and stained with Diff-Quick (Dade Behring).
Collagen Quantification
The Sircol collagen assay (Biocolor) was performed on snap-frozen whole lungs. Lungs were homogenized in 5 ml of 0.5 M acetic acid with 20 mg of pepsin and incubated with shaking for 24 h at 25°C. Homogenate was spun at 4000 rpm, and supernatant was assayed for pepsin soluble collagen according to the manufacturer’s instructions.
Ashcroft scoring
Assessment of pulmonary fibrosis was performed on Masson’s Trichrome-stained lung sections using a minor modification of the method outlined by Ashcroft et al. (40). For our purposes we analyzed 25 fields at x40 per slide using a two-person randomized blind study. At least five mice were used for each group.
Polyethylene glycol (PEG)-conjugated nucleotidase
Crude venom from Crotalus atrox (Sigma-Aldrich) was resuspended in normal saline, and nucleotidase activity was extracted by affinity purification over AMP-Sepharose (Sigma-Aldrich). Weakly bound activity was extracted with 0.1% Triton in saline, and tightly bound activity was extracted with 10 mM AMP. Fractions were pooled and diluted in sterile PBS (pH 9.0), and 40 mg/ml mPEG-SPA (molecular mass 20,000 kDa; Nektar Therapeutics) was added and mixed at room temperature for 4 h. Pegylation efficiency was assessed by zymogram analysis as described previously (41), using AMP as a substrate. Endotoxin was removed using AffinityPak Endotoxin Columns (Pierce). Final product was filter sterilized by passage through a 0.2-µm filter. PEG-modified nucleotidase (P-NT) activity was determined by assaying AMPase by HPLC.
Nucleotidase replacement
Three hours after bleomycin challenge, CD73+/+ or CD73–/– mice were anesthetized with isoflurane and instilled intranasally with 0.5 U of P-NT or PEG alone in 30 µl of normal saline (1 U is defined as activity for the generation of 1 µm adenosine from AMP per min at 37°C). Treatment was repeated on days 4, 8, and 12 of the challenge. Mice were sacrificed and endpoints measured on day 14 after bleomycin challenge.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
To determine whether adenosine generation is altered during the pathogenesis of bleomycin-induced lung injury, adenosine levels and CD73 enzymatic activity were measured following bleomycin challenge. Mice challenged with bleomycin exhibited a 3-fold increase in lung adenosine levels compared with saline-treated controls (Fig. 1A). This elevation was coupled with a similar increase in AMPase (Fig. 1B) in membrane fractions isolated from the lungs of bleomycin-challenged mice. To distinguish CD73 from other AMPase, a specific inhibitor (APCP) was used. Both CD73 and non-CD73 AMPase were elevated upon bleomycin challenge, with 
70% of the AMPase attributed to CD73. These findings demonstrate that adenosine levels are elevated following bleomycin challenge in association with increases in CD73-specific activity.
|
CD73-deficient mice were used to determine the contribution of CD73 to the production of adenosine in the lung (30). CD73-deficient (CD73–/–), heterozygous (CD73+/–), and wild-type (CD73+/+) mice were examined for the presence of CD73 transcript and protein, as well as CD73 and non-CD73 AMPase, distinguished by sensitivity to the CD73-specific inhibitor, APCP. Quantitative RT-PCR on whole lung RNA extracts revealed no CD73 transcripts in CD73–/– mice, and a reduction in CD73 transcripts in CD73+/– mice (Fig. 2A). Similarly, Western blots of lung membrane fractions did not detect CD73 protein in CD73–/– mice (Fig. 2C). Total AMPase in lung membrane fractions was reduced to non-APCP inhibitable levels, whereas non-CD73 activity was unaltered in the lungs of CD73–/– mice (Fig. 2B). These findings demonstrate the absence of CD73 activity in the lungs of CD73–/– mice, and show that there is no compensatory increase in activity of other nucleotidases.
|
To determine whether CD73 activity is required for the accumulation of adenosine following bleomycin challenge, CD73–/– mice were challenged with bleomycin, and nucleosides were quantified (Fig. 3). Whereas CD73+/+ mice exhibited a 3-fold increase in lung adenosine levels, no significant increase in adenosine was seen in the lungs of CD73–/– mice. These data demonstrate that CD73 is responsible for adenosine accumulation that occurs following bleomycin-induced lung injury.
|
To determine the role of adenosine production on inflammation following bleomycin challenge, CD73+/+ and CD73–/– mice were challenged with bleomycin and examined for inflammatory endpoints (Fig. 4). Histological examination revealed little to no interstitial inflammation in CD73+/+ or CD73–/– mice challenged with saline (Fig. 4, A and B). Interstitial inflammation was evident in CD73+/+ mice challenged with bleomycin, but the inflammation was sparse and diffuse (Fig. 4C). In contrast, CD73–/– mice challenged with bleomycin exhibited increased numbers of inflammatory foci in the distal airways (Fig. 4D). Although there were no histologically apparent differences between CD73+/+ and CD73–/– mice following saline challenge, analysis of BAL cellularity revealed a slight but significant elevation in baseline inflammation in the lungs of CD73–/– mice (Fig. 4, E and F). Following bleomycin challenge, there were elevations in cells recovered in the BAL of CD73+/+ mice, and these increases were enhanced in the BAL fluid of CD73–/– mice (Fig. 4, E–G). CD73–/– mice challenged with bleomycin exhibited about a 2.5-fold greater level of total cells recovered in the BAL, as well as significant increases in macrophages, lymphocytes, and neutrophils (Fig. 4, E–G). These data demonstrate that loss of CD73 results in enhanced pulmonary inflammation following bleomycin challenge.
|
Collagen overproduction and deposition are prominent features of bleomycin-induced pulmonary fibrosis (42). Masson’s Trichrome staining revealed increased collagen deposition (blue staining) in the lungs of CD73+/+ mice following bleomycin challenge (Fig. 5, A and C). The degree of collagen deposition was enhanced in the lungs of CD73–/– mice challenged with bleomycin (Fig. 5D). Consistent with these observations, analysis of whole lung RNA revealed an increase in -1-procollagen transcript in bleomycin-treated CD73–/– mice (Fig. 5E). Furthermore, total collagen content was enhanced in the lungs of CD73–/– mice challenged with bleomycin (Fig. 5F). These findings demonstrate that loss of CD73 results in enhanced collagen production and deposition in the lung following exposure to bleomycin.
|
|
Enhanced pulmonary inflammation and fibrosis in the lungs of CD73–/– mice treated with bleomycin prompted us to examine levels of inflammatory and fibrotic mediators (Fig. 7). Transcript levels for the proinflammatory mediators IL-1 (Fig. 7A) and TNF- (Fig. 7B) were found to be elevated in RNA extracts from CD73+/+ mice treated with bleomycin. Furthermore, the levels of these mediators were significantly higher in RNA extracts from the lungs of CD73–/– mice treated with bleomycin (Fig. 7, A and B). Similarly, levels of profibrotic mediators such as TGF-1 (Fig. 7C), OPN (Fig. 7D), PAI-1 (Fig. 7E), and TIMP-1 (Fig. 7F) were enhanced in the lungs of CD73–/– mice treated with bleomycin. These data demonstrate that loss of CD73 is associated with enhanced expression of proinflammatory and profibrotic mediators in the lung following bleomycin exposure.
|
To verify that the absence of CD73 AMPase activity is responsible for the observed effects in CD73–/– mice, exogenous nucleotidase conjugated to PEG (P-NT) was introduced to the lungs of CD73–/– and CD73+/+ mice following bleomycin challenge. Intranasal administration of P-NT to the lungs of CD73–/– mice reduced total cell infiltrates, macrophages, and lymphocytes to levels comparable to those seen in CD73+/+ mice (Fig. 8). Interestingly, introduction of P-NT to the lungs of CD73+/+ mice reduced total cellular infiltrates after bleomycin challenge (Figs. 8 and 9). Similarly, treatment with P-NT resulted in a decrease in collagen deposition and overall fibrosis in the lungs of CD73–/– mice (Fig. 9). These data demonstrate that treatment with exogenous nucleotidase can reverse the effects of CD73 deficiency on bleomycin-induced lung injury.
|
|
Adenosine levels were measured in mice administered P-NT to ensure that exogenous nucleotidase treatment was affecting adenosine levels in the lungs of bleomycin-treated mice. Adenosine levels were found to be elevated in both CD73+/+ and CD73–/– mice following P-NT treatment and bleomycin challenge, but not after saline challenge (Fig. 10). These data demonstrate the ability of P-NT to elevate adenosine levels in CD73–/– mice, suggesting that improvements in bleomycin-induced injury following P-NT treatments are due to elevations in adenosine levels. Furthermore, the observation that introduction of additional AMPase activity can increase adenosine levels in CD73+/+ mice suggests that the conversion of AMP into adenosine is the rate-limiting step in the generation of adenosine in this model.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
A major observation from this study was that the level of CD73 enzymatic activity is up-regulated in the lungs following bleomycin injury in conjunction with elevations in adenosine. This finding, together with the demonstration that deletion of CD73 results in loss of adenosine accumulation, suggests that CD73 up-regulation is an orchestrated and crucial response to regulating extracellular adenosine levels. The regulation of CD73 has been linked to factors that are consistent with this hypothesis. Hypoxia can lead to increased transcription and activity of CD73 (27, 28) in part through mechanisms that involve the transcription factor hypoxia-inducible factor-1 (27). Hypoxia is common in situations of tissue inflammation and injury, and is associated with adenosine elevations (3, 45). Furthermore, CD73 can be up-regulated by adenosine itself through transcriptional regulation via cAMP response element elements in the CD73 promoter (27). Such feed forward regulation of adenosine production emphasizes the necessity of orchestrated generation of this signaling nucleoside. The mechanism by which CD73 is up-regulated in response to bleomycin injury is not known, but the findings in this study provide important in vivo evidence for purinergic remodeling responses in the damaged lung that favor the production of adenosine. In addition, excessive apoptosis occurs in the airways following bleomycin challenge (46), which may contribute to adenosine generation; however, the observations that adenosine levels are elevated in both humans (33, 34) and mice (35, 36, 37) that exhibit features of asthma and chronic obstructive pulmonary disease, suggests that CD73-dependent adenosine generations may be a widespread feature of lung injury. Interestingly, nucleotidase activity is elevated in epithelial cells isolated from cystic fibrosis patients (47), and asthmatics have a unique sensitivity to inhaled AMP (11). Both of these findings suggest that regulated increases in CD73 may play a major role in adenosine-mediated effects in the inflamed lung.
Adenosine has been shown to have an array of differing and sometimes opposing inflammatory effects depending on the type of injury and the tissues involved (4, 5, 6, 48). We demonstrate in this study that reduced adenosine accumulation in the lungs of CD73–/– mice results in enhanced inflammation and fibrosis in response to bleomycin challenge. Inflammatory infiltrates and collagen deposition were increased in the lungs of CD73–/– mice treated with bleomycin, and survival was reduced. In addition, there was enhanced expression of key inflammatory and fibrotic mediators in the lungs of CD73–/– mice given bleomycin. The dependence of this response on the ability to produce adenosine was verified by the reintroduction of exogenous AMPase activity to CD73–/– mice. These findings suggest that adenosine elevations following bleomycin-induced injury are serving an anti-inflammatory and tissue-protective role. These observations are consistent with previous findings implicating an anti-inflammatory and tissue-protective role for CD73-mediated adenosine generation. Under hypoxic conditions, CD73–/– mice exhibit increased vascular leakage and neutrophil accumulation that is reduced by the administration of exogenous AMPase activity (30, 45). Increased vascular leakage was also observed when a specific inhibitor of CD73 (APCP) was acutely administered to normal mice under hypoxic conditions (27, 45). In addition, CD73-mediated adenosine production has been shown to play an important role in regulating inflammation in an air-pouch model of tissue injury (49). These findings, together with the results in the current study suggest that production of adenosine by CD73 is an important pathway for tissue protection.
Consistent with an anti-inflammatory/tissue-protective role for adenosine, we found that CD73+/+ mice challenged with bleomycin and supplemented with exogenous AMPase activity exhibit reduced numbers of inflammatory cells in the BAL fluid. These findings suggest that elevating adenosine production through increasing nucleotidase activity is able to enhance the endogenous anti-inflammatory effects of adenosine. Another interesting observation was that the levels of BAL inflammatory cells in the lungs of unchallenged CD73–/– mice were elevated, suggesting that CD73-mediated adenosine production plays an important role in the homeostatic regulation of tissue inflammation by maintaining endothelial integrity and preventing vessel leakage and leukocyte infiltration (30). These findings suggest that there are ample quantities of extracellular adenine nucleotides available for conversion into adenosine in the normal and injured lung, and that the availability of CD73 enzymatic activity on the cell surface is a limiting factor. Indeed, adenine nucleotides can be produced by multiple cell types including inflammatory cells (16, 17, 18) and airway epithelial cells (19, 20, 21, 22), all of which can contribute to the tropic- and injury-induced production of adenosine by CD73. This raises the possibility of using exogenous nucleotidase-based therapies to regulate adenosine production to benefit certain inflammatory situations. However, additional studies are needed to categorize the effects of adenosine in various injury situations, because excessive or prolonged adenosine elevations may activate pathways that exacerbate inflammation and tissue injury (6).
Previous studies from our laboratory have shown that adenosine can serve as a profibrotic signal in the lung (37). Prolonged elevations in adenosine in the lungs of mice lacking adenosine deaminase are associated with inflammation and airway injury that includes extensive airway fibrosis (37). Furthermore, elevation in endogenous adenosine has profibrotic actions in the lungs of mice with Th2-induced lung disease (35). These studies suggest that elevations in adenosine are sufficient to access profibrotic pathways in the lungs. In contrast, the current study clearly demonstrates that elevations in adenosine are not necessary for the development of pulmonary fibrosis. Understanding this paradox likely lies in the appreciation of the diverse activities of the various ARs (43). The ARs are found on a variety of cells implicated in the regulation of lung inflammation and damage. The A1AR is expressed on macrophages (39) and airway smooth muscle (50), and perhaps airway epithelial cells (39), the A2AAR is present on endothelial cells, macrophages, neutrophils and lymphocytes (5), the A3AR is present on macrophages (51), eosinophils (41, 52), mast cells (53), and mucus-producing epithelial cells (35, 41), and the A2BAR seems to be ubiquitous, being found on all of the aforementioned cells (5, 54) as well as pulmonary fibroblasts and myofibroblasts (55). Whether engagement of these receptors is associated with anti-inflammatory/tissue-protective effects, or proinflammatory/tissue-destructive effects is dictated by the levels of ligand produced, the pattern of receptor expression on various cells, the effector systems coupled to these receptors, and the cytokine or growth factor environment (5, 54).
Anti-inflammatory and tissue-protective effects have been assigned to the A1AR, A2AAR, and A3AR (4, 5, 48). The enhanced inflammation seen in association with the lack of adenosine production in the lungs of bleomycin-challenged CD73–/– mice might represent a loss of anti-inflammatory effects mediated by these ARs. The enhanced production of IL-1 and TNF- in CD73–/– mice treated with bleomycin is consistent with such a hypothesis. Interestingly, TNF- production has been shown to be decreased by engagement of the A2AAR or A3AR (51, 56, 57), suggesting that the absence of damaged-induced adenosine production and engagement of AR anti-inflammatory mechanisms contribute to the enhanced inflammation seen in the lungs of CD73–/– mice exposed to bleomycin. The subsequent augmentation of pulmonary fibrosis might result from increased generation of profibrotic mediators (TGF-1, OPN, PAI-1, TIMP-1) as a result of the enhanced inflammatory response. In the case of adenosine-induced pulmonary fibrosis in other models, the involvement of proinflammatory and/or profibrotic actions of ARs might predominate over anti-inflammatory effects of adenosine. Recent studies have demonstrated that engagement of the A2BAR can drive the transformation of pulmonary fibroblasts into myofibroblasts, suggesting that this receptor has profibrotic activities (55). Interestingly, the A2BAR has a low affinity for adenosine (58), and might only be activated in situations with pronounced adenosine accumulations. Therefore, adenosine might serve anti-inflammatory tissue-protective roles at acute stages of injury, and as damage ensues and adenosine levels rise, profibrotic actions of the A2BAR might contribute to the amplification and progression of pulmonary fibrosis. This theory would emphasize the need to maintain a balance in adenosine production and signaling to ensure proper tissue repair as opposed to propagation of fibrosis. Understanding the regulation and contribution of adenosine production and AR regulation over the course of tissue injury and repair will be paramount to deciphering how this balance is maintained.
In conclusion, we demonstrate that ecto-5'-nucleotidase (CD73) is needed for the generation of adenosine in the lungs of mice exhibiting bleomycin-induced inflammation and fibrosis. In addition, diminished adenosine generation in the lungs of bleomycin-challenged CD73–/– mice was associated with enhanced pulmonary inflammation and fibrosis, suggesting that adenosine has anti-inflammatory and tissue-protective actions in this model. Studies are in progress to assess the specific contribution of individual ARs in bleomycin-induced lung injury with the intent of deciphering the mechanisms associated with both anti-inflammatory/tissue-protective and proinflammatory/tissue-destructive contributions of adenosine to pulmonary fibrosis.
|
Acknowledgments |
|---|
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 This work was supported by National Institutes Health Grants AI-43572 and HL-70952 (to M.R.B.) and AI-18220 (to L.F.T.). Portions of this work were also supported by a career investigator award from the American Lung Association (to M.R.B.). 
2 Address correspondence and reprint requests to Dr. Michael R. Blackburn, Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Medical School, 6431 Fannin Street, Houston, TX 77030. E-mail address: michael.r.blackburn{at}uth.tmc.edu
3 Abbreviations used in this paper: AR, adenosine receptor; APCP, -methylene ADP; AMPase, AMP hydrolytic activity; OPN, osteopontin; PAI-1, plasminogen activator inhibitor-1; TIMP-1, tissue inhibitor of metalloproteinase-1; BAL, bronchial alveolar lavage; PEG, polyethylene glycol; P-NT, polyethylene glycol-modified nucleotidase.
Received for publication November 15, 2005. Accepted for publication January 24, 2006.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
in bleomycin-mouse model of lung fibrosis: downregulation of TGF- and procollagen I and III gene expression. Exp. Lung Res. 21: 791-808. [Medline] expression by adenosine: role of A3 adenosine receptors. J. Immunol. 156: 3435-3442. [Abstract], and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157: 4634-4640. [Abstract] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 14: 2065-2074. This article has been cited by other articles:
|
|
 |
|
  S. Nakav, O. Naamani, C. Chaimovitz, G. Shaked, D. Czeiger, M. Zlotnik, and A. Douvdevani Regulation of adenosine system at the onset of peritonitis Nephrol. Dial. Transplant., October 26, 2009; (2009) gfp542v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Eckle, M. Koeppen, and H. K. Eltzschig Role of Extracellular Adenosine in Acute Lung Injury Physiology, October 1, 2009; 24(5): 298 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhou, A. Mohsenin, E. Morschl, H. W. J. Young, J. G. Molina, W. Ma, C.-X. Sun, H. Martinez-Valdez, and M. R. Blackburn Enhanced Airway Inflammation and Remodeling in Adenosine Deaminase-Deficient Mice Lacking the A2B Adenosine Receptor J. Immunol., June 15, 2009; 182(12): 8037 - 8046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Katebi, M. Soleimani, and B. N. Cronstein Adenosine A2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development J. Leukoc. Biol., March 1, 2009; 85(3): 438 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Reutershan, I. Vollmer, S. Stark, R. Wagner, K.-C. Ngamsri, and H. K. Eltzschig Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs FASEB J, February 1, 2009; 23(2): 473 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Morschl, J. G. Molina, J. B. Volmer, A. Mohsenin, R. S. Pero, J.-S. Hong, F. Kheradmand, J. J. Lee, and M. R. Blackburn A3 Adenosine Receptor Signaling Influences Pulmonary Inflammation and Fibrosis Am. J. Respir. Cell Mol. Biol., December 1, 2008; 39(6): 697 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Hart, D. Kohler, T. Eckle, D. Kloor, G. L. Stahl, and H. K. Eltzschig Direct Treatment of Mouse or Human Blood With Soluble 5'-Nucleotidase Inhibits Platelet Aggregation Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1477 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Mills, L. F. Thompson, C. Mueller, A. T. Waickman, S. Jalkanen, J. Niemela, L. Airas, and M. S. Bynoe CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis PNAS, July 8, 2008; 105(27): 9325 - 9330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Peng, P. Fernandez, T. Wilder, H. Yee, L. Chiriboga, E. S. L. Chan, and B. N. Cronstein Ecto-5'-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis FASEB J, July 1, 2008; 22(7): 2263 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takedachi, D. Qu, Y. Ebisuno, H. Oohara, M. L. Joachims, S. T. McGee, E. Maeda, R. P. McEver, T. Tanaka, M. Miyasaka, et al. CD73-Generated Adenosine Restricts Lymphocyte Migration into Draining Lymph Nodes J. Immunol., May 1, 2008; 180(9): 6288 - 6296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Louis, A. M. Robinson, C. F. MacManus, J. Karhausen, M. Scully, and S. P. Colgan Control of IFN-{alpha}A by CD73: Implications for Mucosal Inflammation J. Immunol., March 15, 2008; 180(6): 4246 - 4255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hasko and P. Pacher A2A receptors in inflammation and injury: lessons learned from transgenic animals J. Leukoc. Biol., March 1, 2008; 83(3): 447 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Eckle, L. Fullbier, M. Wehrmann, J. Khoury, M. Mittelbronn, J. Ibla, P. Rosenberger, and H. K. Eltzschig Identification of Ectonucleotidases CD39 and CD73 in Innate Protection during Acute Lung Injury J. Immunol., June 15, 2007; 178(12): 8127 - 8137. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) or without (
) APCP. Data are presented as mean picomoles of AMP converted to adenosine per minute per milligram of protein ± SEM (n = 8; *, p < 0.05).
) and lymphocytes (
